Mylan’s merger with Pfizer’s off-patent branded drugs unit Upjohn is now expected to close in the second half of this year due to the coronavirus pandemic.
As a result of restrictions on large gatherings in the Netherlands, Mylan’s extraordinary general meeting of shareholders to approve certain matters for the transaction has been postponed from 27 April to 30 June.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
There were no other amendments to previously announced terms or plans related to the merger.
